- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OPTIMA MEDICAL INNOVATIONS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 3,578 | +1,36 % | Aurora Rejects Curaleaf's Higher Bid, But the Takeover Fight Isn't Over | ||
| CANOPY GROWTH | 0,640 | +0,79 % | Trump's Marijuana Order Is Stuck at the DEA. Here's What That Means for Canopy Growth. | ||
| TILRAY BRANDS | 2,735 | +1,11 % | Tilray's Q1 Results Show A Company Transformed | ||
| ABBOTT LABORATORIES | 91,32 | -0,09 % | Tagesvorschau 15. Oktober: Daten-Donnerstag: Abbott, United Airlines und US-Einzelhandel im Fokus | Quartalsbilanzen von Paris bis Chicago treffen auf frische US-Daten - dieser Donnerstag hat es in sich.Am Donnerstag kommen Berichtssaison und Konjunkturdaten zusammen. In Europa stehen am Morgen der... ► Artikel lesen | |
| SINOPHARM | 1,772 | +4,14 % | SINOPHARM (01099): ANNOUNCEMENT PRELIMINARY FINANCIAL DATA OF SINOPHARM ACCORD FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2026 | ||
| AMARIN | 9,950 | -3,40 % | Amarin Corporation plc: Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence | Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 16,830 | -7,53 % | Acadia Pharmaceuticals Inc.: European Commission Approves DAYBU (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 60,04 | -0,17 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
| AURINIA PHARMACEUTICALS | 14,500 | -2,72 % | Alliance Advisors LLC: Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences | Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer... ► Artikel lesen | |
| CNBX PHARMACEUTICALS | - | - | CNBX Pharmaceuticals bestellt neuen Abschlussprüfer | ||
| ARGENT BIOPHARMA | 0,011 | 0,00 % | ARGENT BIOPHARMA LIMITED: Notice of Annual General Meeting/Proxy Form | ||
| CENTR BRANDS | 0,007 | 0,00 % | Centr Brands Corp (2): Centr Brands extends maturity dates of debentures | ||
| LABORATORIOS FARMACEUTICOS ROVI | 58,95 | +0,08 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| AVECHO BIOTECHNOLOGY | 0,011 | -100,00 % | AVECHO BIOTECHNOLOGY LIMITED: Response to ASX Price Query | ||
| HERON THERAPEUTICS | 0,313 | -1,14 % | Heron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI Patents | CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court... ► Artikel lesen |
Das Unternehmen OPTIMA MEDICAL INNOVATIONS CORP kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OPTIMA MEDICAL INNOVATIONS CORP finden Sie auf Wallstreet Online.